Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group

Chemical and Pharmaceutical Bulletin

Volumn 53, Issue 7, 2005, Pages 764-769

  Shimada, Yoshiaki ^a   Akane, Hiroaki ^a   Taniguchi, Nobuaki ^a   Matsuhisa, Akira ^a   Kawano, Noriyuki ^a   Kikuchi, Kazumi ^a   Yatsu, Takeyuki ^a   Tahara, Atsuo ^a   Tomura, Yuichi ^a   Kusayama, Toshiyuki ^a   Wada, Koh Ichi ^a   Tsukada, Junko ^a   Tsunoda, Takashi ^a   Tanaka, Akihiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

2 Ethyl 1H 1 imidazole; Arginine vasopressin; V1A receptor selective antagonist

Indexed keywords

2 (1H 1,2,4 TRIAZOL 1 YL) 4' [(2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL)CARBONYL]BENZANILIDE; 2 (1H IMIDAZOL 1 YL) 4' [(2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL)CARBONYL]BENZANILIDE; 2 (2 ETHYL 1H IMIDAZOL 1 YL) 4' [(2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL)CARBONYL]BENZANILIDE; 2 (2 METHYL 1H IMIDAZOL 1 YL) 4' [(2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL)CARBONYL]BENZANILIDE; 2 (2 PHENYL 1H IMIDAZOL 1 YL) 4' [(2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL)CARBONYL]BENZANILIDE; 2 (2 PROPYL 1H IMIDAZOL 1 YL) 4' [(2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL)CARBONYL]BENZANILIDE; 2 PHENYL 4' [(2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL)CARBONYL]BENZANILIDE; 4' [(2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL)CARBONYL] 2 (1H TETRAZOL 5 YL)BENZANILIDE; 4' [(5 CARBAMOYLMETHYLENE 4,4 DIFLUORO 2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL)CARBONYL] 2 (2 ETHYL 1H IMIDAZOL 1 YL)BENZANILIDE; 4' [[4,4 DIFLUORO 5 (2 MORPHOLINO 2 OXOETHYLIDENE) 2,3,4,5 TETRAHYDRO 1H 1 YL]CARBONYL] 2 (2 ETHYL 1H 1 IMIDAZOL 1 YL)BENZANILIDE; 4' [[4,4 DIFLUORO 5 [(N (2 METHOXYETHYL)CARBAMOYL]METHYLENE] 2,3,4,5 TETRAHYDRO 1H 1 YL]CARBONYL] 2 (2 ETHYL 1H 1 IMIDAZOL 1 YL)BENZANILIDE; 4' [[4,4 DIFLUORO 5 [(N 1 PROPYLCARBAMOYL)METHYLENE] 2,3,4,5 TETRAHYDRO 1H 1 YL]CARBONYL] 2 (2 ETHYL 1H 1 IMIDAZOL 1 YL)BENZANILIDE; 4' [[4,4 DIFLUORO 5 [(N 2 PROPYLCARBAMOYL)METHYLENE] 2,3,4,5 TETRAHYDRO 1H 1 YL]CARBONYL] 2 (2 ETHYL 1H 1 IMIDAZOL 1 YL)BENZANILIDE; 4' [[4,4 DIFLUORO 5 [(N CYCLOPROPYLCARBAMOYL)METHYLENE] 2,3,4,5 TETRAHYDRO 1H 1 YL]CARBONYL] 2 (2 ETHYL 1H 1 IMIDAZOL 1 YL)BENZANILIDE; 4' [[4,4 DIFLUORO 5 [(N ETHYLCARBAMOYL)METHYLENE] 2,3,4,5 TETRAHYDRO 1H 1 YL]CARBONYL] 2 (2 ETHYL 1H 1 IMIDAZOL 1 YL)BENZANILIDE; 4' [[4,4 DIFLUORO 5 [(N METHYLCARBAMOYL)METHYLENE] 2,3,4,5 TETRAHYDRO 1H 1 YL]CARBONYL] 2 (2 ETHYL 1H 1 IMIDAZOL 1 YL)BENZANILIDE; 4' [[4,4 DIFLUORO 5 [(N,N DIETHYLCARBAMOYL)METHYLENE] 2,3,4,5 TETRAHYDRO 1H 1 YL]CARBONYL] 2 (2 ETHYL 1H 1 IMIDAZOL 1 YL)BENZANILIDE; 4' [[4,4 DIFLUORO 5 [(N,N DIMETHYLCARBAMOYL)METHYLENE] 2,3,4,5 TETRAHYDRO 1H 1 YL]CARBONYL] 2 (2 ETHYL 1H 1 IMIDAZOL 1 YL)BENZANILIDE; 4' [[4,4 DIFLUORO 5 [2 OXO 2 (1 PIPERIDINYL)ETHYLIDENE] 2,3,4,5 TETRAHYDRO 1H 1 YL]CARBONYL] 2 (2 ETHYL 1H 1 IMIDAZOL 1 YL)BENZANILIDE; 4' [[5 [(4 DIMETHYLAMINOPIPERIDINO)CARBONYLMETHYLENE] 4,4 DIFLUORO 2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL]CARBONYL] 2 PHENYLBENZANILIDE; ANILIDE; ARGININE VASOPRESSIN V1A RECEPTOR ANTAGONIST; ARGIPRESSIN RECEPTOR; IMIDAZOLE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; NONHUMAN; RAT;

ARGININE VASOPRESSIN; IMIDAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; RECEPTORS, VASOPRESSIN; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT;

EID: 24944527847     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.53.764     Document Type: Article

References (16)

1. Hardman J. G., Limbird L. E., "Goodman & Gilman's The Pharmacological Basis of Therapeutics," 10th ed., Chap. 30, McGraw-Hill, New York, 2001, pp. 789-808.
2. Michel R. H., Kirk C. J., Billah M. M., Biochem. Soc. Trans., 7, 861-865 (1979).
3. Jard S., Kidney Int., Supp., 26, 38-42 (1988).
4. Sugimoto T., Saito M., Mochizuki S., Watanabe Y., Hashimoto S., Kawashima H., J. Biol. Chem., 269, 27088-27092 (1994).
5. Yatsu T., Tomura T., Tahara A., Wada K., Tsukada J., Uchida W., Tanaka A., Takenaka T., Eur. J. Pharmacol., 321, 225-230 (1997).
6. Ogawa H., Yamamura Y., Miyamoto H., Kondo K., Yamashita H., Nakaya K., Chihara T., Mori T., Tominaga M., Yabuuchi Y., J. Med. Chem., 36, 2011-2017 (1993).
7. Serradeil-Li Gal C., Wagnon J., Garcia C., Lacour C., Guiraudou P., Christophe B., Villanova G., Nisato D., Maffrand J. P., Le Fur G., Guillon G., Cantau B., Barberis C., Trueba M., Ala Y., Jard S., J. Clin. Invest., 92, 224-231 (1993).
8. Shimada Y., Taniguchi N., Matsuhisa A., Yatsu T., Tahara A., Tanaka A., Chem. Pharm. Bull., 51, 1075-1080 (2003).
9. Matsuhisa A., Taniguchi N., Koshio H., Yatsu T., Tanaka A., Chem. Pharm. Bull., 48, 21-31 (2000).
10. Shimada Y., Taniguchi N., Matsuhisa A., Sakamoto K., Yatsu T., Tanaka A., Chem. Pharm. Bull., 48, 1644-1651 (2000).
11. Matsuhisa A., Tanaka A., Kikuchi K., Shimada Y., Yatsu T., Yanagisawa I., Chem. Pharm. Bull., 45, 1870-1874 (1997).
12. Stabler S. R., Jahangir, Synth. Commun., 24, 123-129 (1994).
13. Chapman E., Stephan H., J. Chem. Soc., 127, 1791-1797 (1925).
14. Sauers C. K., Cotter R. J., J. Org. Chem., 26, 6-10 (1961).
15. Thomas A. P., Allott C. P., Gibson K. H., Major J. S., Masek B. B., Oldham A. A., Ratcliffe A. H., Roberts D. A., Russel S. T., Thomason D. A., J. Med. Chem., 35, 877-885 (1992).
16. Kricheldorf H. R., Leppert E., Synthesis, 1976, 329-330 (1976).